Astellas to Support Development of Taysha's AAV-based Gene Therapy Programs

  Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic central nervous system diseases with serious unmet medical needs -

- Astellas to invest a total of $50 million to acquire 15% of the company and to receive an exclusive option to obtain an exclusive license for TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN) -

- Astellas to receive certain rights related to any potential change of control of Taysha -

- Astellas to receive one Board observer seat on the Taysha Board of Directors -

https://finance.yahoo.com/news/astellas-taysha-gene-therapies-announce-233000296.html